EGF-ERBB signalling: Towards the systems level

Ami Citri, Yosef Yarden*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1669 Scopus citations


Signalling through the ERBB/HER receptors is intricately involved in human cancer and already serves as a target for several cancer drugs. Because of its inherent complexity, it is useful to envision ERBB signalling as a bow-tie-configured, evolvable network, which shares modularity, redundancy and control circuits with robust biological and engineered systems. Because network fragility is an inevitable trade-off of robustness, systems-level understanding is expected to generate therapeutic opportunities to intercept aberrant network activation.

Original languageAmerican English
Pages (from-to)505-516
Number of pages12
JournalNature Reviews Molecular Cell Biology
Issue number7
StatePublished - 17 Jul 2006
Externally publishedYes

Bibliographical note

Funding Information:
We thank B. Kholodenko, S. H. Wiley, M. Hatakeyama and P. De-Meyts for insightful comments. Our laboratory is supported by research grants from the National Cancer Institute, the Israel Science Foundation, the Israel Cancer Research Fund, the Prostate Cancer Foundation and the German-Israel Foundation. Y.Y. is the incumbent of the Harold and Zelda Goldenberg Professorial Chair.


Dive into the research topics of 'EGF-ERBB signalling: Towards the systems level'. Together they form a unique fingerprint.

Cite this